Alnylam Pharmaceuticals (ALNY) presents a compelling bullish thesis with a $39.06 billion market cap, trailing P/E of 73.51, forward P/E of 30.67, TTM EPS of $3.98, and 96.4% year-over-year revenue growth to $4.29 billion, reflecting strong profitability momentum in its RNAi platform. The stock trades well below its 52-week high of $495.55 with a low beta of 0.30, supported by overwhelming analyst consensus (22 buy/strong buy ratings vs. 8 holds) and a $445.81 average target price.

Key catalysts include continued commercial expansion of approved RNAi therapies like Onpattro, Amvuttra, and Givlaari, alongside a robust pipeline targeting rare diseases and potential label expansions that drove the 96.4% revenue surge; earnings momentum remains positive with 12.6% profit margins and $3.47 billion gross profit TTM, positioning the company for sustained double-digit growth as RNAi technology gains broader adoption.

Risks center on regulatory hurdles for new approvals, intense competition in biotechnology, and macro pressures like interest rates affecting biotech valuations, though these are mitigated by Alnylam's first-mover advantage in RNAi, diversified pipeline, and strong institutional ownership at 102%. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.